Kaken Pharmaceutical Co., Ltd. (Tokyo Stock Exchange: 4971) is a Tokyo-based pharmaceutical company with a focus on orthopedics, dermatology, and central nervous system disorders. The company has a long history in Japan dating back to 1948 and has developed several important CNS drugs.
| Attribute |
Details |
| Founded |
1948 |
| Headquarters |
Tokyo, Japan |
| Stock |
TSE Prime (4971) |
| Market Cap |
Approximately ¥40-60 billion |
| Focus Areas |
Orthopedics, Dermatology, CNS |
- 1948: Founded as pharmaceutical manufacturer in Japan
- 1960s: Expansion into orthopedic and dermatological products
- 1980s: Development of CNS portfolio
- 2000s: Strategic partnerships with international pharma
- Present: Diversified pharmaceutical company with CNS focus
- Pain management for orthopedic conditions
- Osteoporosis treatments
- Anti-inflammatory agents
- Topical treatments
- Skin disease therapeutics
Kaken has been involved in research related to:
- Neuropathic pain: Development of treatments for chronic neuropathic pain conditions
- Pain modulation: Targeting pain signaling pathways
- Peripheral neuropathy: Diabetic neuropathy and other conditions
Research into anti-inflammatory approaches for CNS disorders:
- Microglia modulation
- Cytokine pathway inhibitors
- Neuroprotective anti-inflammatory approaches
Early-stage research programs targeting:
- Research into dopaminergic therapies
- Motor symptom management
- Neuroprotection approaches
| Product |
Indication |
Category |
| Various orthopedic agents |
Orthopedic pain |
Marketed |
| Alendronate |
Osteoporosis |
Marketed (licensed from Merck) |
| CNS agents |
Neurological disorders |
Marketed |
| Program |
Indication |
Stage |
| Pain management |
Neuropathic pain |
Marketed |
| Anti-inflammatory |
CNS inflammation |
Research |
| Bone metabolism |
Osteoporosis |
Marketed |
| AD program |
Alzheimer's disease |
Discovery |
¶ Partnerships and Collaborations
- Licensing agreements with international pharmaceutical companies
- Distribution partnerships for Japanese market
- Collaborations with Japanese universities
- Research partnerships with Japanese research institutions
- Work with PMDA (Pharmaceuticals and Medical Devices Agency)
- Compliance with MHLW regulations
Japan represents a significant market for pharmaceutical development:
- Aging population: Growing elderly population increases demand for CNS therapies
- Regulatory environment: PMDA provides robust regulatory framework
- Research infrastructure: Strong academic and industry research capabilities
- Market size: Third largest pharmaceutical market globally
¶ Competitive Landscape
Kaken competes with major Japanese pharmaceutical companies:
Kaken's position in the Japanese market:
- Niche focus: Orthopedic and dermatological expertise
- CNS expansion: Growing neuroscience portfolio
- Partnership model: Licensing and distribution agreements
- Domestic strength: Strong Japan market presence
| Therapeutic Area |
Market Position |
| Orthopedics |
Top 5 in Japan |
| Dermatology |
Top 10 in Japan |
| CNS |
Emerging player |
- Expand CNS portfolio: Develop novel CNS therapeutics
- Partnership model: License international products for Japan
- Aging population focus: Target CNS diseases affecting elderly
- Generic expansion: Develop generic versions of off-patent CNS drugs
- Revenue: ~¥50 billion (2024)
- R&D investment: ~15% of revenue
- Operating margin: ~10%
- Employees: ~2,500
| Detail |
Information |
| Exchange |
Tokyo Stock Exchange Prime |
| Ticker |
4971 |
| Market cap |
~¥50 billion |
| Dividend |
Annual dividend paid |
¶ Quality and Compliance
Kaken maintains rigorous quality standards:
- PMDA compliance: Fully compliant with Japanese pharmaceutical regulations
- GMP certification: All facilities GMP-certified
- ISO certifications: ISO 9001, ISO 14001
- Regular inspections: Both internal and regulatory audits